Jiangsu Aidea Pharmaceutical Co Ltd (688488) - Total Assets
Based on the latest financial reports, Jiangsu Aidea Pharmaceutical Co Ltd (688488) holds total assets worth CN¥1.84 Billion CNY (≈ $269.97 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Jiangsu Aidea Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Jiangsu Aidea Pharmaceutical Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Jiangsu Aidea Pharmaceutical Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Jiangsu Aidea Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Aidea Pharmaceutical Co Ltd's total assets of CN¥1.84 Billion consist of 47.9% current assets and 52.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.9% |
| Accounts Receivable | CN¥183.84 Million | 9.8% |
| Inventory | CN¥254.97 Million | 13.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥180.41 Million | 9.7% |
| Goodwill | CN¥171.62 Million | 9.2% |
Asset Composition Trend (2016–2024)
This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688488 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Aidea Pharmaceutical Co Ltd's current assets represent 47.9% of total assets in 2024, an increase from 37.7% in 2016.
- Cash Position: Cash and equivalents constituted 17.9% of total assets in 2024, up from 7.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, unchanged from 18.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 13.6% of total assets.
Jiangsu Aidea Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Aidea Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Jiangsu Aidea Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 1.51 | 13.79 |
| Quick Ratio | 1.03 | 1.11 | 12.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥263.87 Million | CN¥314.99 Million | CN¥933.72 Million |
Jiangsu Aidea Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Aidea Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.53 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | 7.0% |
| Total Assets | CN¥1.87 Billion |
| Market Capitalization | $773.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Aidea Pharmaceutical Co Ltd's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jiangsu Aidea Pharmaceutical Co Ltd's assets grew by 7.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total assets of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.87 Billion ≈ $273.58 Million |
+7.04% |
| 2023-12-31 | CN¥1.75 Billion ≈ $255.58 Million |
+5.52% |
| 2022-12-31 | CN¥1.66 Billion ≈ $242.21 Million |
+15.38% |
| 2021-12-31 | CN¥1.43 Billion ≈ $209.93 Million |
-0.84% |
| 2020-12-31 | CN¥1.45 Billion ≈ $211.72 Million |
+85.26% |
| 2019-12-31 | CN¥780.98 Million ≈ $114.28 Million |
+10.16% |
| 2018-12-31 | CN¥708.95 Million ≈ $103.74 Million |
+7.54% |
| 2017-12-31 | CN¥659.24 Million ≈ $96.47 Million |
+48.63% |
| 2016-12-31 | CN¥443.55 Million ≈ $64.91 Million |
-- |
About Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. The company offers anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products… Read more